PFIZER INC.
| Revenue | $63.7B |
|---|---|
| Operating income | $2.5B |
| Net income | $2.4B |
| Free cash flow | $11.0B |
| Operating margin | 4.0% |
| Net margin | 3.8% |
| Return on equity | 2.9% |
| Period | TTM 2026-06-28 |
OpenFilings analyst
Our analyst
Agentic read of the latest earnings call — recommendation updates when we process a new transcript. Research synthesis, not investment advice.
Promising Phase 2b profile, but pivotal evidence and differentiation remain unproven.
Pfizer’s berobenatide readout is encouraging but not yet a buy catalyst:
monthly dosing produced up to 12.3% placebo-corrected weight loss at week 28, while high-dose weekly extension data showed approximately 16% weight loss at week 32 and generally favorable GI tolerability. However, the core efficacy case relies heavily on cross-trial comparisons and model-based projections, high-dose monthly tolerability remains unproven, and Pfizer declined to pursue head-to-head studies—leaving meaningful competitive and execution risk ahead of a targeted 2028 weekly approval.
- Berobenatide
- Obesity
- Monthly Glp1
- Phase 3
- Vesper Trials
- Amylin Combination
Near term
Enrollment and design updates from the 10-study Phase 3 program, particularly monthly VESPER-6 and the global switch study.
Additional 2026 data from the berobenatide/amylin combination could strengthen or weaken the broader metabolic franchise thesis.
Investor focus will remain on whether the reduced weekly-to-monthly dose step-up improves on the low-to-mid-20% vomiting rates seen in some Phase 2b active arms.
Longer term
A successful monthly product could expand initiation, switching and persistence in a large obesity market; Pfizer cites fewer than 10% of eligible adults currently on therapy and a market expected to exceed $100 billion.
The commercial thesis depends on monthly convenience translating into real-world adherence and switching, but the cited 51% patient preference and 86% provider intent are survey results rather than clinical persistence evidence.
Efficacy appears competitive on indirect comparisons, but Lilly and Novo Nordisk have established products and Pfizer has not committed to head-to-head trials that could validate superiority or meaningful differentiation.
The planned weekly launch followed by a monthly fast follow may create an installed base, but it also exposes Pfizer to competition before the most differentiated monthly formulation is available.
Combination therapy with the ultra-long-acting amylin analog could become a major upside driver, though it is only entering Phase 2b and remains clinically unvalidated.
Red flags
Management repeatedly emphasized that high-dose monthly tolerability is not yet supported by clinical data; the 9.6 mg monthly dose has not been tested in the reported dataset.
The efficacy case uses cross-trial comparisons and a 69-trial model-based meta-analysis, despite management acknowledging that these methods cannot establish definitive comparative efficacy.
When analysts asked about head-to-head trials, Pfizer said it did not see a clear need to conduct them. That limits the evidence base for claims that berobenatide matches tirzepatide or beats semaglutide.
Management offered no quantified expected share, pricing, revenue contribution, or switching rate; the commercial case remains largely dependent on hypothetical research and qualitative confidence.
The projected 2028 approval timeline is conditional on pivotal success and regulatory review, while monthly approval is expected only as a fast follow to weekly approval.
OpenFilings analyst view from primary-source filings and earnings calls — not investment advice.
From latest 10-K · 2026-02-26
- Revenue Decline
- Covid Revenue Normalization
- Adjusted Earnings Gap
- Metsera Acquisition
- Pipeline Impairments
- Debt Load
- Pricing Pressure
- Manufacturing Optimization
Red flags
- Long-term debt principal increased to $61.29 billion from $57.15 billion in 2024, with $2.997 billion of current long-term debt and additional 2025 borrowings used partly for the Metsera acquisition.
- GAAP diluted EPS of $1.36 was less than half adjusted diluted EPS of $3.22, reflecting $4.874 billion of intangible amortization, $1.285 billion of acquisition-related items and $4.940 billion of certain asset impairments in the reconciliation.
- Net cash flow from operations fell 8% to $11.7 billion despite adjusted EPS growth, limiting internally generated funding for debt reduction, dividends and additional acquisitions.
- The company recorded $4.94 billion of certain asset impairments in 2025, including $3.9 billion related to IPR&D, highlighting the risk that acquired pipeline investments fail clinically or commercially.
- Legal contingencies include patent, product liability, antitrust, pricing and government matters; Pfizer says it cannot estimate the range of reasonably possible losses above accrued amounts.